Rule | Jotup

NeuroSense Regains Compliance with NASDAQ Minimum Bid Price Rule

Retrieved on:

Wednesday, February 7, 2024

CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.

Key Points:

CAMBRIDGE, Mass., Feb. 7, 2024 /PRNewswire/ -- NeuroSense Therapeutics Ltd. (Nasdaq: NRSN) ("NeuroSense"), a company developing treatments for severe neurodegenerative diseases, today announced that it has received notice from The Nasdaq Stock Market LLC ("Nasdaq") informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing.
To regain compliance with the Rule, the Company's ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 6, 2024.
Therefore, the Nasdaq Listing Qualifications Staff considers the prior bid price deficiency matter now closed.
NeuroSense's CEO, Alon Ben-Noon said, "Regaining compliance with the Nasdaq minimum bid price listing requirement is an important event as we continue to focus on the advancement of PrimeC following the recently announced positive top-line results from the Phase 2b PARADIGM trial.

Ares Capital Corporation Announces December 31, 2023 Financial Results and Declares First Quarter 2024 Dividend of $0.48 Per Share

Retrieved on:

Wednesday, February 7, 2024

In the fourth quarter of 2023, Ares Capital made new investment commitments of approximately $2.4 billion, of which approximately $1.6 billion were funded.

Key Points:

In the fourth quarter of 2023, Ares Capital made new investment commitments of approximately $2.4 billion, of which approximately $1.6 billion were funded.
Also in the fourth quarter of 2023, Ares Capital funded approximately $297 million related to previously existing unfunded revolving and delayed draw loan commitments.
On October 24, 2023, Ares Capital announced that its Board of Directors declared a fourth quarter 2023 dividend of $0.48 per share for a total of approximately $280 million.
The fourth quarter 2023 dividend was paid on December 28, 2023 to stockholders of record as of December 15, 2023.

Processa Pharmaceuticals Regains Compliance with Nasdaq Minimum Bid Price Rule

Retrieved on:

Tuesday, February 6, 2024

Rule, Patient, Safety, Cancer, PCSA

Processa is a clinical stage pharmaceutical company focused on developing the Next Generation Chemotherapy (NGC) drugs to improve the safety and efficacy of cancer treatment. By combining Processa’s novel oncology pipeline with proven cancer-killing active molecules and Processa’s Regulatory Science Approach as well as experience in defining Optimal Dosage Regimens for FDA approvals, Processa not only will be providing better therapy options to cancer patients but also increase the probability of FDA approval for its Next Generation Chemotherapy (NGC) drugs following an efficient path to approval. The Company’s approach to drug development, based on more than 30 years of drug development experience, uses its proven Regulatory Science Approach, including the determination of the Optimal Dosage Regimen using the principles of the FDA’s Project Optimus Oncology initiative. Processa’s NGC drugs are modifications of existing FDA-approved oncology drugs resulting in an alteration of the metabolism and/or distribution of these FDA-approved drugs while maintaining the existing mechanisms of killing the cancer cells. The advantages of Processa’s NGCs are expected to include fewer patients experiencing side effects that lead to dose discontinuation, more significant cancer response, and a greater number of patients -- over 250,000 patients treated each year for each drug -- who will benefit from each NGC drug. Currently under development are three next generation chemotherapy oncology treatments: Next Generation Capecitabine (PCS6422 and capecitabine to treat breast, metastatic colorectal, gastrointestinal, pancreatic, and other cancers), Next Generation Gemcitabine (PCS3117 to treat pancreatic, lung, ovarian, breast, and other cancers), and Next Generation Irinotecan (PCS11T to treat lung, colorectal, gastrointestinal, pancreatic, and other cancers).

Key Points:

HANOVER, MD, Feb. 06, 2024 (GLOBE NEWSWIRE) -- Processa Pharmaceuticals, Inc. (Nasdaq: PCSA) (“Processa” or the “Company”), a clinical-stage pharmaceutical company focused on developing the next generation of chemotherapeutic drugs to improve the efficacy and safety for more patients suffering from cancer, announces it has received notice from The Nasdaq Stock Market LLC (“Nasdaq”) informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the “Rule”) for continued listing on the Nasdaq Market and that the matter is now closed.
To regain compliance with the Rule, the Company’s ordinary shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days, which was achieved on February 2, 2024.

Numerous Amici Join NCLA’s Ask for Supreme Court to Rule Against ATF’s Unilateral Bump Stock Ban

Retrieved on:

Friday, February 2, 2024

Representing Texas gun shop owner and Army veteran Michael Cargill, NCLA challenges the Bureau of Alcohol, Tobacco, Firearms and Explosives’ Bump Stock Final Rule and ATF’s expansion of the criminal scope of a statute by administrative fiat.

Key Points:

Representing Texas gun shop owner and Army veteran Michael Cargill, NCLA challenges the Bureau of Alcohol, Tobacco, Firearms and Explosives’ Bump Stock Final Rule and ATF’s expansion of the criminal scope of a statute by administrative fiat.
The Final Rule reversed ATF’s long-standing recognition that bump-stock-equipped firearms are not illegal machine guns, and the U.S. Court of Appeals for the Fifth Circuit rightly shot down the Rule early last year.
NCLA thanks the amicus parties for standing with Mr. Cargill and thousands of other legal purchasers of bump stocks.
Excerpts follow:
“In the best tradition of our separation of powers jurisprudence, this Court should apply the criminal laws that Congress has written with unmistakable clarity.

Agrify Receives Positive Nasdaq Listing Determination

Retrieved on:

Wednesday, January 31, 2024

Hearing, Rule, Exercise, Staff, Panel, Security (finance)

TROY, Mich., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Capital Market pursuant to an extension through April 15, 2024, to evidence compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires listed companies to have a stockholders’ equity of at least $2.5 million for continued listing on The Nasdaq Capital Market.

Key Points:

TROY, Mich., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Capital Market pursuant to an extension through April 15, 2024, to evidence compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires listed companies to have a stockholders’ equity of at least $2.5 million for continued listing on The Nasdaq Capital Market.
The Company earlier received notice from the Listing Qualifications Staff of Nasdaq indicating that the Company no longer satisfied the Rule and was therefore subject to delisting.
In response, the Company timely requested a hearing before the Panel, which request stayed any further action by the Staff.
Furthermore, as previously announced, on November 30, 2023, the New Lender forgave $1,000,000 in debt owed by the Company.

Agrify Receives Positive Nasdaq Listing Determination

Retrieved on:

Wednesday, January 31, 2024

Hearing, Rule, Exercise, Staff, Panel, Security (finance)

TROY, Michigan, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Capital Market pursuant to an extension through April 15, 2024, to evidence compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires listed companies to have a stockholders’ equity of at least $2.5 million for continued listing on The Nasdaq Capital Market.

Key Points:

TROY, Michigan, Jan. 31, 2024 (GLOBE NEWSWIRE) -- Agrify Corporation (Nasdaq: AGFY) (“Agrify” or the “Company”), a leading provider of innovative cultivation and extraction solutions for the cannabis industry, today announced that the Company has received formal notification that the Nasdaq Hearings Panel (the “Panel”) has granted the Company’s request for continued listing on The Nasdaq Capital Market pursuant to an extension through April 15, 2024, to evidence compliance with Nasdaq Listing Rule 5550(b)(1) (the “Rule”), which requires listed companies to have a stockholders’ equity of at least $2.5 million for continued listing on The Nasdaq Capital Market.
The Company earlier received notice from the Listing Qualifications Staff of Nasdaq indicating that the Company no longer satisfied the Rule and was therefore subject to delisting.
In response, the Company timely requested a hearing before the Panel, which request stayed any further action by the Staff.
Furthermore, as previously announced, on November 30, 2023, the New Lender forgave $1,000,000 in debt owed by the Company.

The Future of IT Applications in the Digital Age: Guide to Transforming Application Development and Delivery Published by Info-Tech Research Group

Retrieved on:

Tuesday, January 30, 2024

Today, Growth, Research, AI, Natural language processing, Rule, Machine learning, Agile, Natural language, Artificial intelligence, Risk, Creativity, Exception, Stakeholder, Management

Addressing this new pivotal change and how IT leaders can navigate it, Info-Tech Research Group, a global leader in IT research and advisory, has published its latest blueprint, Exponential IT for Applications .

Key Points:

Addressing this new pivotal change and how IT leaders can navigate it, Info-Tech Research Group, a global leader in IT research and advisory, has published its latest blueprint, Exponential IT for Applications .
This approach will help align IT more closely with business objectives and the evolving demands of the digital marketplace.
"Today, IT is set up to deliver applications and platforms to solve business challenges in a servant-like relationship.
The new blueprint underscores the transformative impact of adopting a strategic, people-centric approach within application development and delivery.

First Hawaiian, Inc. Reports Fourth Quarter 2023 Financial Results and Declares Dividend

Retrieved on:

Friday, January 26, 2024

Hawaii–Aleutian Time Zone, Total, Trust, Insurance, ATM, First Hawaiian Bank, FHB, Rule, Webcast, Security (finance), Airline

Net income of $47.5 million, or $0.37 per diluted share

Key Points:

Net income of $47.5 million, or $0.37 per diluted share
Total assets were $24.9 billion at December 31, 2023 and September 30, 2023.
Net interest income for the fourth quarter of 2023 was $151.8 million, a decrease of $5.4 million, or 3.4%, compared to $157.1 million for the prior quarter.
The net interest margin was 2.81% in the fourth quarter of 2023, a decrease of 5 basis points compared to 2.86% in the prior quarter.
Noninterest income was $58.3 million in the fourth quarter of 2023, an increase of $12.3 million compared to noninterest income of $46.1 million in the prior quarter.

SAB Biotherapeutics Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on:

Tuesday, January 23, 2024

Immunotherapy, T1D, SAB, Rule

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

Key Points:

SIOUX FALLS, S.D., Jan. 23, 2024 (GLOBE NEWSWIRE) -- SAB Biotherapeutics , Inc. (Nasdaq: SABS ), (SAB), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing fully-human anti-thymocyte immunoglobulin (hIgG) for delaying the onset or progression of type 1 diabetes (T1D), today announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on January 23, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.
On January 23, 2023, SAB received notice from Nasdaq that the Company was not in compliance with the Rule, as its common shares failed to meet a closing bid price of $1.00 or more for 30 consecutive business days.
The Company conducted a 1-for-10 reverse split of its common shares on January 5, 2024, to aid the compliance process.
To regain compliance with the Rule, the Company’s common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.

Versus Systems Regains Compliance with Nasdaq Minimum Bid Price Requirement

Retrieved on:

Thursday, January 18, 2024

Rule

LOS ANGELES, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on January 16, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.

Key Points:

LOS ANGELES, Jan. 18, 2024 (GLOBE NEWSWIRE) -- Versus Systems Inc. (“Versus” or the “Company”) (Nasdaq: VS) announced that it received notice from The Nasdaq Stock Market LLC ("Nasdaq") on January 16, 2024 informing the Company that it has regained compliance with the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2) (the "Rule") for continued listing on the Nasdaq Capital Market.
On January 23, 2023, Versus received notice from Nasdaq that the Company was not in compliance with the Rule, as its common shares failed to meet a closing bid price of $1.00 or more for 30 consecutive business days.
The Company conducted a 1-for-16 reverse split of its common shares on December 28, 2023 to aid the compliance process.
To regain compliance with the Rule, the Company’s common shares were required to maintain a minimum closing bid price of $1.00 or more for at least 10 consecutive business days.